TrialBlood advances2020

Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant.

Scott R Solomon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.